Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth

Solventum Corporation (NYSE:SOLV) is one of the cheap new stocks to buy now. On February 26, Solventum reported Q4 2025 financial results that exceeded expectations, despite a reported sales decline of 3.7% to $2 billion. This decrease was driven by the divestiture of the company’s Purification and Filtration business in September 2025. However, organic sales grew by 3.5%. The company achieved GAAP diluted EPS of $0.36 and adjusted diluted EPS of $1.57, fueled by debt reduction following the recent divestiture and operational efficiencies that helped offset incremental tariff headwinds.

The MedSurg segment, Solventum’s largest, led the growth with a 6.2% reported increase in Infection Prevention and Surgical Solutions. Dental Solutions also showed strong momentum with an 8.6% reported sales increase, while Health Information Systems grew by 3.7%. However, the company’s free cash flow for the quarter was $33 million, a drop from the prior year’s $92 million, reflecting the costs associated with its transformation into a standalone entity following its spin-off from 3M.

Solventum Corporation (NYSE:SOLV) introduced its full-year 2026 guidance, projecting organic sales growth between 2.0% and 3.0%. This forecast includes an estimated 100-basis-point negative impact from strategic SKU exits as the company streamlines its portfolio. Management expects adjusted EPS to range from $6.40 to $6.60 and anticipates a significant recovery in free cash flow to ~$200 million.

Solventum Corporation (NYSE:SOLV) is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the US and internationally. It has three segments: Medsurg, Dental Solutions, and Health Information Systems.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Dirt Cheap Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.